Case Study 37.1 — Two ❌s That Mean Opposite Things

BPC-157 for tendon healing, beside nesiritide for heart failure outcomes

Why these two

Scan the master table and both compounds carry the same glyph. BPC-157 for tendon and soft-tissue healing in humans: ❌. Nesiritide for death or rehospitalization in adults hospitalized with acute decompensated heart failure: ❌.

If the glyph were all you had, you would conclude the two situations are equivalent. They are close to opposite. This case study is the exercise of pulling them apart, because the distinction it teaches — §37.3's two kinds of ❌ — is the one readers most reliably get backwards and the one that does the most work when a new compound arrives.

Compound one: BPC-157

The claim rated. BPC-157 accelerates healing of tendon and soft-tissue injuries in humans. Rated in Chapter 5 and again in Chapter 17. ❌ both times.

What exists. A large preclinical literature, much of it from a small number of research groups, reporting effects across an unusually wide range of injury models. A fifteen-residue sequence that is consistent across sources. An active consumer market. Extensive anecdotal reporting.

What does not exist. As of this writing, one completed, peer-reviewed, randomized controlled human trial of the compound for this indication. Not a failed one. Not an equivocal one. None.

What that means about the state of knowledge. We do not know whether BPC-157 accelerates tendon healing in humans. That sentence is uncomfortable in both directions, and it is the accurate one. The ❌ is fully earned, because the confident claims made for the compound outrun anything that has been demonstrated in people. But the ❌ is about a blank page. It records the absence of an answer, not the presence of a negative one.

Why the page is blank. Chapter 38 §38.10 gives the mechanism, and it is not suppression. A phase 3 program is expensive and slow, and it gets funded by entities that can recoup the cost through a period of exclusive sale. A compound that cannot be protected has no such sponsor. The absence of trials here is an economic fact, not an evidentiary one — which is exactly why it tells you so little about whether the compound works.

Compound two: nesiritide

The claim rated. Infused nesiritide (recombinant human BNP) improves clinical outcomes — death or rehospitalization — in adults hospitalized with acute decompensated heart failure. Rated in Chapter 28. ❌, and marked (N) in the master table.

What exists. A great deal. Nesiritide reached approval on hemodynamic surrogates and short-term symptom measures. It was then studied in a randomized, placebo-controlled outcome trial of roughly 7,100 patients, which found no meaningful effect on death or rehospitalization.

What that means about the state of knowledge. We know. A serious, funded, adequately powered attempt was made to demonstrate that this molecule improves the outcomes that matter, and the effect did not appear. That result cost an enormous amount of money and years of patient participation, and what it purchased is certainty of a kind that is genuinely rare.

Note also what the same chapter rates ✅. Measuring BNP or NT-proBNP to help diagnose heart failure — particularly to exclude it — in adults presenting with undifferentiated breathlessness is ✅. And a third row, titrating heart failure therapy toward an NT-proBNP target, is ❌ and also marked (N): the trial testing that strategy was stopped for futility. The same peptide system is a good measurement, a bad target, and an ineffective drug, and nothing about the mechanism predicted which would be which.

The comparison, side by side

                              BPC-157                      NESIRITIDE
                              (tendon healing)             (HF outcomes)

  Glyph                       ❌                            ❌
  Kind of ❌                   evidence ABSENT               evidence PRESENT AND NEGATIVE
  Adequate human trials?      none completed                run, large, placebo-controlled
  What we can say             "we do not know"              "we looked; it isn't there"
  Cost of the knowledge       nothing was spent             a great deal was spent
  Likelihood the row moves    high — nothing anchors it     low — the question was answered
  Direction if it moves       either way                    almost certainly stays
  Marketed with "no evidence
    against it"?              constantly                    never

The last line is the tell described in §37.3. The slogan absence of evidence is not evidence of absence is available only for compounds in the left column. Nobody deploys it for nesiritide, because the evidence is not absent.

The trap

The intuitive reading runs backwards, and it runs backwards for a reason worth naming.

"The trials failed" sounds like an unfinished story. Maybe the population was wrong, maybe the endpoint was wrong, maybe the next attempt succeeds. "There are no trials" sounds like open territory, and in a consumer market that emptiness is sold as promise.

Invert it. The compound with failed trials is the one about which something specific and expensive is known. The compound with no trials is the one about which nothing is known — including, and this is the part that gets lost, nothing systematic about its safety. An evidence-absent ❌ means nobody ran the efficacy trial, and the same absence usually applies to safety data collection. Chapter 19's rating of "nobody has reported any problems" is ❌ for precisely this reason: no reporting pathway exists for unapproved products, so an absence of reports reflects an absence of collection.

Questions

1. Write the one-sentence honest summary of what is known about each compound's rated claim. Then say which sentence would be more useful to a person deciding what to do, and why the more useful one is the more uncomfortable one.

2. Both rows are ❌. If you had to predict which will read differently in 2031, which do you choose, and what specific event would produce the change? Name the event, not just the direction.

3. Chapter 28 rates the BNP system three ways: ✅ for diagnosis, ❌ (N) for biomarker-guided titration, ❌ (N) for infusing the peptide. Explain how one molecular system earns three different ratings without any inconsistency, and identify which rule from §37.2 you are applying.

4. A seller argues: "Nesiritide failed, which proves peptides in this space don't work. BPC-157 has never failed a trial." Identify both errors, and say which one is more dangerous to a reader who has learned the glyphs but not §37.3.

5. Suppose a randomized controlled trial of BPC-157 for tendon healing reports next year with a positive result on a functional endpoint. Using the five-step update procedure in §37.9, list what you would need to know before moving the row, and state the highest tier a single positive trial could move it to.

6. † The nesiritide story begins with an approval granted on hemodynamic surrogates. Find two other rows in the master table that currently rest on surrogate endpoints and are rated ✅ or ⚠️. For each, state what the corresponding hard-outcome trial would have to show for the rating to survive — and say whether you would bet on it.